Effect of antipsychotic medications on glucose and lipid levels

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 631-638

  Chaggar, Parminder S ^a   Shaw, Steven M ^b   Williams, Simon G ^b  

^a Basildon Thurrock University Hospitals Foundation NHS Trust   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular; clinical trials; glucose; lipid metabolism; psychiatry

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; DEMENTIA; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; ORAL GLUCOSE TOLERANCE TEST; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN RESISTANCE; LIPIDS; RISK ASSESSMENT; RISK FACTORS;

EID: 79955529007     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010368678     Document Type: Review

References (31)

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998 ; 173: 11-53 (Pubitemid 28312203)
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006 ; 3: A42
3. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005 ; 150: 1115-1121 (Pubitemid 41773510)
4. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001 ; 35: 196-202 (Pubitemid 32377538)
5. Fernandez-Egea E, Bernardo M, Parellada E, et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res. 2008 ; 103: 110-113
6. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008 ; 69 (suppl 1). 4-17
7. Thase ME. Maintenance therapy for bipolar disorder. J Clin Psychiatry. 2008 ; 69: e32
8. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006 ; 186: 572-578
9. Saddichha S, Manjunatha N, Ameen S, et al. Diabetes and schizophrenia-effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008 ; 117: 342-347 (Pubitemid 351502438)
10. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003 ; 160: 290-296 (Pubitemid 41110454)
11. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008 ; 69: 790-799 (Pubitemid 351838688)
12. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 ; 86: 234-243 (Pubitemid 44251272)
13. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007 ; 68: 1733-1740 (Pubitemid 350247503)
14. Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol. 2007 ; 22: 145-152 (Pubitemid 46559870)
15. Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006 ; 26: 157-162 (Pubitemid 43740339)
16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223 (Pubitemid 41345943)
17. Emsley R, Turner HJ, Schronen J, et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol. 2005 ; 8: 175-182 (Pubitemid 40769258)
18. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004 ; 65: 696-701
19. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005 ; 13: 722-730 (Pubitemid 41197244)
20. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005 ; 162: 1879-1887 (Pubitemid 41428617)
21. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007 ; 22: 433-443 (Pubitemid 47600616)
22. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004 ; 19: 115-126 (Pubitemid 38247846)
23. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008 ; 69: 1046-1056 (Pubitemid 352031586)
24. Tovey E, Rampes H, Livingstone C. Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice. J Psychopharmacol. 2005 ; 19: 207-210 (Pubitemid 40577227)
25. Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007 ; 32: 765-772 (Pubitemid 46426168)
26. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001 ; 35: 1381-1387 (Pubitemid 33042072)
27. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005 ; 162: 1535-1538 (Pubitemid 41105572)
28. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008 ; 33: 985-994 (Pubitemid 351367540)
29. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006 ; 189: 259-266 (Pubitemid 44691547)
30. Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res. 2008 ; 103: 104-109
31. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007 ; 68 (suppl 4). 4-7 (Pubitemid 46762117)